Page 135 - Binder2

And if our clinical trials don’t reflect that timeline, we’re
not testing real therapies.
We’re testing placeholders—molecules that might work
briefly, but can’t hold their ground.

Designing for immune durability means rebuilding the
evidence model from the ground up.
It means trials that don’t just ask, “Does it work?”—but
also, “Does it last?”

Because until we build biologics to endure, every therapy
will carry an unspoken expiration date.

And the clock starts ticking the moment it’s approved.

3.6 – From Patchwork to Platform

Right now, the biologics ecosystem operates like a series of
disconnected reactions.

A drug fails? Switch.
Efficacy wanes? Add methotrexate.
ADAs rise? Escalate the dose.
Symptoms return? Try another within the same class.

Each step is a workaround—reactive, incremental, and
often expensive.
There’s no unifying architecture, no longitudinal immune
strategy, and no commitment to true compatibility.
Just a cascade of temporary solutions.

This is the patchwork model of biologic development:

133